Advanced search
Publication Cover
Pharmacogenomics Volume 15, 2014 - Issue 5
Submit an article Journal homepage
162
Views
0
CrossRef citations to date
0
Altmetric
Research Article

A Polymorphism in the promoter is Associated with EZH2 Expression but not with Outcome in Advanced Pancreatic Cancer Patients

Mina Maftouh1 Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, CCA room 1.52, De Boelelaan 1117, 1081HVAmsterdam, The NetherlandsView further author information
,
Amir Avan1 Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, CCA room 1.52, De Boelelaan 1117, 1081HVAmsterdam, The NetherlandsView further author information
,
Niccola Funel2 Department of Surgery & Surgical Pathology, University of Pisa, ItalyView further author information
,
Elisa Paolicchi3 Department of Internal Medicine, University of Pisa, ItalyView further author information
,
Enrico Vasile4 Department of Oncology, University of Pisa, Pisa, ItalyView further author information
,
Paola Pacetti5 Department of Medical Oncology, Carrara Civic Hospital, Carrara, ItalyView further author information
,
Vanja Vaccaro6 Department of Medical Oncology A, Regina Elena National Cancer Institute, Roma, ItalyView further author information
,
Pinuccia Faviana2 Department of Surgery & Surgical Pathology, University of Pisa, ItalyView further author information
,
Daniela Campani2 Department of Surgery & Surgical Pathology, University of Pisa, ItalyView further author information
,
Sara Caponi4 Department of Oncology, University of Pisa, Pisa, ItalyView further author information
,
Andrea Mambrini5 Department of Medical Oncology, Carrara Civic Hospital, Carrara, ItalyView further author information
,
Ugo Boggi2 Department of Surgery & Surgical Pathology, University of Pisa, ItalyView further author information
,
Maurizio Cantore5 Department of Medical Oncology, Carrara Civic Hospital, Carrara, ItalyView further author information
,
Michele Milella6 Department of Medical Oncology A, Regina Elena National Cancer Institute, Roma, ItalyView further author information
,
Godefridus J Peters1 Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, CCA room 1.52, De Boelelaan 1117, 1081HVAmsterdam, The NetherlandsView further author information
,
Michele Reni7 Department of Medical Oncology, San Raffaele Scientific Institute, Milan, ItalyView further author information
&
Elisa Giovannetti1 Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, CCA room 1.52, De Boelelaan 1117, 1081HVAmsterdam, The Netherlands;8 Start-Up Unit, University of Pisa, Pisa, ItalyCorrespondence[email protected]
View further author information
 show all
Pages 609-618 | Published online: 05 May 2014

References

  • Vincent A , HermanJ, SchulickR, HrubanRH, GogginsM. Pancreatic cancer. Lancet378(9791) , 607–620 (2011).
  • Makohon-Moore A , BrosnanJA, Iacobuzio-DonahueCA. Pancreatic cancer genomics: insights and opportunities for clinical translation. Genome Med.5(33) , 26 (2013).
  • Toll AD , DasguptaA, PotoczekM et al. Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma. Hum. Pathol. 41(9) , 1205–1209 (2010).
  • Viré E , BrennerC, DeplusR et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 16(7078) , 871–874 (2006).
  • Qi W , ChanH, TengL et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc. Natl Acad. Sci. USA 109(52) , 21360–21365 (2012).
  • Chang CJ , YangJY, XiaW et al. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell 19(1) , 86–100 (2011).
  • Avan A , CreaF, PaolicchiE et al. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol. Cancer Ther. 11(8) , 1735–1746 (2012).
  • Ougolkov AV , BilimVN, BilladeauDD. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase EZH2. Clin. Cancer Res.14(21) , 6790–6796 (2008).
  • Yoon KA , GilHJ, HanJ, ParkJ, LeeJS. Genetic polymorphisms in the polycomb group gene EZH2 and the risk of lung cancer. J. Thorac. Oncol.5(1) , 10–16 (2010).
  • Crea F , FornaroL, PaolicchiE et al. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Ann. Oncol. 23(5) , 1207–1213 (2012).
  • Fornaro L , CreaF, MasiG et al. EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. Ann. Oncol.23(5) , 1370–1371 (2012).
  • Cardoso C , MignonC, HetetG et al. The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders. Eur. J. Hum. Genet. 8(3) , 174–180 (2000).
  • Yang CH , ChengYH, ChuangLY, ChangHW. Drug-SNPing: an integrated drug-based, protein interaction-based tagSNP-based pharmacogenomics platform for SNP genotyping. Bioinformatics29(6) , 758–764 (2013).
  • Yu YL , SuKJ, HsiehYH et al. Effects of EZH2 polymorphisms on susceptibility to and pathological development of hepatocellular carcinoma. PLoS ONE 8(9) , e74870 (2013).
  • Giovannetti E , Del Tacca M, Mey V et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res.66(7) , 3928–3935 (2006).
  • Giovannetti E , FunelN, PetersGJ et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 70(11) , 4528–4538 (2010).
  • Avan A , PacettiP, ReniM et al. Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back. Int. J. Cancer 133(4) , 1016–1022 (2013).
  • Giovannetti E , PacettiP, ReniM et al. Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics 12(12) , 1641–1652 (2011).
  • Qazi AM , GruzdynO, SemaanA et al. Restoration of E-cadherin expression in pancreatic ductal adenocarcinoma treated with microRNA-101. Surgery 152(4) , 704–711 (2012).
  • Caponi S , FunelN, FramptonAE et al. The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms. Ann. Oncol. 24(3) , 734–741 (2013).
  • Smits M , NilssonJ, MirSE et al. miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget 1(8) , 710–720 (2010).
  • Chase A , CrossNC. Aberrations of EZH2 in cancer. Clin. Cancer Res.17(9) , 2613–2618 (2011).
  • Oncomine. www.oncomine.org/resource/login.html
  • Gao L , AnticT, HyjekE et al. Immunohistochemical analysis of E-cadherin and zeste homolog 2 expression in endoscopic ultrasound-guided fine-needle aspiration of pancreatic adenocarcinoma. Cancer Cytopathol. doi:10.1002/cncy.21310 (2013) (Epub ahead of print).
  • RNAfold web server. http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi
  • Li CH , ToKF, TongJH et al. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin. Gastroenterology 144(5) , 1086–1097 (2013).
  • Giovannetti E , ErozenciA, SmitJ, DanesiR, PetersGJ. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit. Rev. Oncol. Hematol.81(2) , 103–122 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.